Phase III KEYNOTE-204 trial reports improvement in progression-free survival (PFS) with pembrolizumab versus brentuximab vedotin (BV) in patients with classical Hodgkin lymphoma

Pembrolizumab reduced risk of disease progression or death (one of dual primary endpoints) by 35% (HR 0.65; 95% CI, 0.48-0.88; p=0.00271) and showed a median PFS of 13.2 vs. 8.3 months for BV, a current standard of care in this population. Regulatory submissions planned for 2020.


Biospace Inc.